China SXT Current Financial Leverage
| SXTC Stock | USD 1.07 0.01 0.94% |
China SXT Pharmaceuticals holds a debt-to-equity ratio of 0.681. At present, China SXT's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Long Term Debt is expected to grow to about 142.3 K, whereas Net Debt is projected to grow to (11.6 M). China SXT's financial risk is the risk to China SXT stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
China SXT's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. China SXT's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps China Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect China SXT's stakeholders.
For most companies, including China SXT, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running China SXT Pharmaceuticals the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 0.0539 | Book Value 6.974 | Operating Margin (9.95) | Return On Assets (0.46) | Return On Equity (1.42) |
China |
China SXT Financial Leverage Rating
China SXT Pharmaceuticals bond ratings play a critical role in determining how much China SXT have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for China SXT's borrowing costs.China SXT Pharmaceuticals Debt to Cash Allocation
As China SXT Pharmaceuticals follows its natural business cycle, the capital allocation decisions will not magically go away. China SXT's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 3.76 M in liabilities with Debt to Equity (D/E) ratio of 0.68, which is about average as compared to similar companies. China SXT Pharmaceuticals has a current ratio of 1.28, suggesting that it may have difficulties to pay its financial obligations when due. Debt can assist China SXT until it has trouble settling it off, either with new capital or with free cash flow. So, China SXT's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like China SXT Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for China to invest in growth at high rates of return. When we think about China SXT's use of debt, we should always consider it together with cash and equity.China SXT Total Assets Over Time
China SXT Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the China SXT's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of China SXT, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a a China SXT debt ratio should be compared their industry average or other competing firms.China Short Term Debt
Short Term Debt |
|
Understaning China SXT Use of Financial Leverage
China SXT financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures China SXT's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of China SXT assets, the company is considered highly leveraged. Understanding the composition and structure of overall China SXT debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to China SXT's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of China SXT's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short Term Debt | 3.9 M | 4.1 M | |
| Short and Long Term Debt Total | 4.3 M | 4.5 M | |
| Net Debt | -12.3 M | -11.6 M | |
| Short and Long Term Debt | 3.8 M | 2.1 M | |
| Long Term Debt | 135.5 K | 142.3 K | |
| Net Debt To EBITDA | 2.29 | 2.40 | |
| Debt To Equity | 0.23 | 0.16 | |
| Interest Debt Per Share | 3.66 | 2.11 | |
| Debt To Assets | 0.11 | 0.07 | |
| Long Term Debt To Capitalization | 0.02 | 0.02 | |
| Total Debt To Capitalization | 0.18 | 0.11 | |
| Debt Equity Ratio | 0.23 | 0.16 | |
| Debt Ratio | 0.11 | 0.07 | |
| Cash Flow To Debt Ratio | (0.02) | (0.03) |
Currently Active Assets on Macroaxis
When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:Check out the analysis of China SXT Fundamentals Over Time. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for China Stock analysis
When running China SXT's price analysis, check to measure China SXT's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China SXT is operating at the current time. Most of China SXT's value examination focuses on studying past and present price action to predict the probability of China SXT's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China SXT's price. Additionally, you may evaluate how the addition of China SXT to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is China SXT's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (26.95) | Revenue Per Share 3.65 | Quarterly Revenue Growth (0.22) | Return On Assets (0.46) |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.